KR100857734B1 - 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법 - Google Patents
6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법 Download PDFInfo
- Publication number
- KR100857734B1 KR100857734B1 KR1020077017807A KR20077017807A KR100857734B1 KR 100857734 B1 KR100857734 B1 KR 100857734B1 KR 1020077017807 A KR1020077017807 A KR 1020077017807A KR 20077017807 A KR20077017807 A KR 20077017807A KR 100857734 B1 KR100857734 B1 KR 100857734B1
- Authority
- KR
- South Korea
- Prior art keywords
- group
- alkyl
- phenyl
- amino
- methyl
- Prior art date
Links
- 0 **(N(*)*)=*1c2ccc(*)cc2N(*=I)C1=* Chemical compound **(N(*)*)=*1c2ccc(*)cc2N(*=I)C1=* 0.000 description 2
- UGIOACMSGGVRIA-NSCUHMNNSA-N C/C=C(\C(N1)=O)/NC1=O Chemical compound C/C=C(\C(N1)=O)/NC1=O UGIOACMSGGVRIA-NSCUHMNNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19949208.5 | 1999-10-13 | ||
DE19949208A DE19949208A1 (de) | 1999-10-13 | 1999-10-13 | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10042696.4 | 2000-08-31 | ||
DE2000142696 DE10042696A1 (de) | 2000-08-31 | 2000-08-31 | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027004701A Division KR100835546B1 (ko) | 1999-10-13 | 2000-10-09 | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물 및 이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070095996A KR20070095996A (ko) | 2007-10-01 |
KR100857734B1 true KR100857734B1 (ko) | 2008-09-10 |
Family
ID=26006858
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077017807A KR100857734B1 (ko) | 1999-10-13 | 2000-10-09 | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법 |
KR1020027004701A KR100835546B1 (ko) | 1999-10-13 | 2000-10-09 | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물 및 이의 제조방법 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027004701A KR100835546B1 (ko) | 1999-10-13 | 2000-10-09 | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물 및 이의 제조방법 |
Country Status (42)
Families Citing this family (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
ATE399766T1 (de) | 2000-10-20 | 2008-07-15 | Eisai R&D Man Co Ltd | Stickstoff enthaltende aromatische heterozyklen |
US6638965B2 (en) | 2000-11-01 | 2003-10-28 | Boehringer Ingelheim Pharma Kg | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions |
DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DK1401416T5 (da) | 2001-06-29 | 2007-03-19 | Ab Science | Anvendelse af C-kit-inhibitorer til behandling af inflammatorisk tarmsygdom |
WO2003003006A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
JP2004537536A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | アレルギー疾患を治療するためのチロシンキナーゼ阻害剤の使用方法 |
CA2452361A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
JP2004537537A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法 |
WO2003027102A1 (en) * | 2001-09-27 | 2003-04-03 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
US6797825B2 (en) | 2001-12-13 | 2004-09-28 | Abbott Laboratories | Protein kinase inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
DE60205776T2 (de) | 2001-12-27 | 2006-06-14 | Theravance Inc | Indolinon-derivative als protein-kinasehemmer |
SE0302546D0 (sv) | 2003-09-24 | 2003-09-24 | Astrazeneca Ab | New compounds |
ITBO20020198A1 (it) * | 2002-04-12 | 2003-10-13 | Univ Bologna | Derivati 2 , 5 bis diammino 1 , 4 benzochenionici utili per il trattamento della malattia di alzheimer , metodo per la loro preparazione ed |
US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
DE10233500A1 (de) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel |
DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
US20040204458A1 (en) | 2002-08-16 | 2004-10-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of Lck inhibitors for treatment of immunologic diseases |
US7148249B2 (en) * | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
JP4879492B2 (ja) * | 2002-11-27 | 2012-02-22 | アラーガン、インコーポレイテッド | 疾患の治療のためのキナーゼ阻害剤 |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
CN101337930B (zh) | 2003-11-11 | 2010-09-08 | 卫材R&D管理有限公司 | 脲衍生物的制备方法 |
SE0401790D0 (sv) * | 2004-07-07 | 2004-07-07 | Forskarpatent I Syd Ab | Tamoxifen response in pre- and postmenopausal breast cancer patients |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
EP1797877A4 (en) | 2004-09-13 | 2010-12-15 | Eisai Co Ltd | JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR |
US8772269B2 (en) | 2004-09-13 | 2014-07-08 | Eisai R&D Management Co., Ltd. | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors |
AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
PE20060777A1 (es) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
WO2007057397A1 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
CN101443009A (zh) | 2006-05-18 | 2009-05-27 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
EP1870400A1 (en) * | 2006-06-08 | 2007-12-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Salts and crystalline salt forms of an 2-indolinone derivative |
US8865737B2 (en) | 2006-08-28 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Antitumor agent for undifferentiated gastric cancer |
JP5319306B2 (ja) | 2007-01-29 | 2013-10-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌治療用組成物 |
EP2167465A1 (en) * | 2007-06-12 | 2010-03-31 | Boehringer Ingelheim International GmbH | Indolinone derivatives and their use in treating disease-states such as cancer |
JP5385268B2 (ja) | 2007-06-21 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | インドリン−2−オンおよびアザ−インドリン−2−オン |
KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
PE20091445A1 (es) * | 2007-12-03 | 2009-10-19 | Boehringer Ingelheim Int | Derivados de indolinona y procedimiento para su fabricacion |
EP2229359B1 (en) * | 2007-12-03 | 2017-11-29 | Boehringer Ingelheim International GmbH | Process for the manufacture of an indolinone derivative |
DK2985025T3 (en) | 2008-06-06 | 2018-03-19 | Boehringer Ingelheim Int | PHARMACEUTICAL COMPOSITION |
CA2731919A1 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | New compounds |
US20120157472A1 (en) | 2009-01-14 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Method for treating colorectal cancer |
US8802384B2 (en) | 2009-03-12 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method or system using biomarkers for the monitoring of a treatment |
WO2010108503A1 (en) | 2009-03-24 | 2010-09-30 | Life & Brain Gmbh | Promotion of neuronal integration in neural stem cell grafts |
EP2647375A1 (en) | 2009-05-14 | 2013-10-09 | Boehringer Ingelheim International Gmbh | Combination of vargatef and dabigatran for the treatment of oncological and fibrotic diseases |
US20120107304A1 (en) | 2010-04-27 | 2012-05-03 | Boehringer Ingelheim International Gmbh | Combination therapy in treatment of oncological and fibrotic diseases |
WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
WO2012068441A2 (en) | 2010-11-19 | 2012-05-24 | Ratiopharm Gmbh | Intedanib salts and solid state forms thereof |
US8962650B2 (en) | 2011-04-18 | 2015-02-24 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
US9040555B2 (en) | 2012-01-26 | 2015-05-26 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
WO2014086102A1 (zh) | 2012-12-06 | 2014-06-12 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的吲哚满酮衍生物 |
MX2015004979A (es) | 2012-12-21 | 2015-07-17 | Eisai R&D Man Co Ltd | Forma amorfa de derivado de quinolina y metodo para su produccion. |
EP2945652B1 (en) | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US20140350022A1 (en) | 2013-05-10 | 2014-11-27 | Boehringer Ingelheim International Gmbh | Efficacious treatment of NSCLC and predictive clinical marker of the responsiveness of a tumour to a treatment |
JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
CN104003925B (zh) * | 2013-06-05 | 2016-03-30 | 四川大学 | 吲哚酮化合物或其衍生物及其用途 |
WO2015009889A1 (en) * | 2013-07-18 | 2015-01-22 | Concert Pharmaceuticals, Inc. | Deuterated intedanib derivatives and their use for the treatment of proliferative disorders |
WO2015017728A1 (en) | 2013-07-31 | 2015-02-05 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
EP3825305A1 (en) | 2014-08-28 | 2021-05-26 | Eisai R&D Management Co., Ltd. | Process for preparing lenvatinib |
CN104262232B (zh) * | 2014-09-09 | 2016-05-04 | 苏州明锐医药科技有限公司 | 尼泰达尼的制备方法 |
PT3263106T (pt) | 2015-02-25 | 2024-01-12 | Eisai R&D Man Co Ltd | Método para suprimir o amargor do derivado de quinolina |
AU2015384801B2 (en) | 2015-03-04 | 2022-01-06 | Eisai R&D Management Co., Ltd. | Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer |
WO2016178064A1 (en) | 2015-05-06 | 2016-11-10 | Suven Life Sciences Limited | Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof |
CN104844499B (zh) * | 2015-06-05 | 2017-03-08 | 北京康立生医药技术开发有限公司 | 一锅法制备尼达尼布的合成方法 |
KR20240043821A (ko) | 2015-06-06 | 2024-04-03 | 클라우드브레이크 테라퓨틱스, 엘엘씨 | 익상편을 치료하기 위한 조성물 및 방법 |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
CN105126909B (zh) * | 2015-07-13 | 2018-01-23 | 淮海工学院 | 固载钯催化剂在4‑苯乙炔基‑3‑硝基苯甲酸甲酯合成中的应用 |
CZ308695B6 (cs) | 2015-07-29 | 2021-03-03 | Zentiva, K.S. | Způsob přípravy methyl (Z)-3[[4-[methyl[2-(4-methyl-1piperazinyl)acetyl]amino]fenyl]amino]fenylmethylen)-oxindol-6karboxylátu (intedanibu, nintedanibu) |
CN106467500A (zh) * | 2015-08-14 | 2017-03-01 | 廊坊百瑞化工有限公司 | 一种一锅煮法合成尼达尼布关键中间体的新方法 |
RS64703B1 (sr) * | 2015-12-24 | 2023-11-30 | Respivert Ltd | Jedinjenja indolinona i njihova upotreba u lečenju fibroznih bolesti |
CZ2016104A3 (cs) | 2016-02-24 | 2017-09-06 | Zentiva, K.S. | Krystalické modifikace solí methyl (3Z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}fenyl)amino](fenyl)methyliden}-2-oxo-2,3-dihydro-1H-indol-6-karboxylátu a způsoby jejich přípravy |
CA3017308A1 (en) | 2016-03-08 | 2017-09-14 | Respivert Limited | Indole derivatives and their use as protein kinase inhibitors |
US20190160054A1 (en) | 2016-04-13 | 2019-05-30 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib, trifluridine and tipiracil for treating colorectal cancer |
EP3246029A1 (en) | 2016-05-19 | 2017-11-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer |
EP3464240A1 (en) | 2016-05-27 | 2019-04-10 | Boehringer Ingelheim International GmbH | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
WO2017207643A1 (en) | 2016-06-01 | 2017-12-07 | Boehringer Ingelheim International Gmbh | Use of ecm biomarkers for the determining the treatment onset with nintedanib and pirfenidone |
KR102408596B1 (ko) | 2016-06-02 | 2022-06-13 | 에이디에스 테라퓨틱스 엘엘씨 | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 |
CN114569606B (zh) | 2016-07-29 | 2024-04-19 | 英克特诺治疗公司 | 吲哚啉酮化合物的用途 |
CN106748960A (zh) * | 2016-11-30 | 2017-05-31 | 瑞阳制药有限公司 | 尼达尼布的潜在杂质化合物、制备方法、应用及其检测方法 |
CN106748961A (zh) * | 2016-11-30 | 2017-05-31 | 瑞阳制药有限公司 | 尼达尼布的杂质化合物、制备方法、应用及其检测方法 |
JP2019536812A (ja) | 2016-12-12 | 2019-12-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | オロダテロールとの同時投与による間質性肺疾患の処置方法に使用するためのニンテダニブ |
CN110573161A (zh) | 2017-03-28 | 2019-12-13 | 勃林格殷格翰国际有限公司 | 用于治疗肌营养不良的方法的尼达尼布 |
CN111278442B (zh) | 2017-10-23 | 2023-06-06 | 勃林格殷格翰国际有限公司 | 用于治疗进行性纤维化间质性肺病(pf-ild)的活性剂的新组合 |
CA3082714A1 (en) | 2017-11-17 | 2019-05-23 | Fermion Oy | Synthesis of a 2-indolinone derivative known as intermediate for preparing nintedanib |
JP7061310B2 (ja) * | 2018-04-05 | 2022-04-28 | 国立大学法人 大分大学 | 慢性脂肪性疾患の予防および治療用医薬 |
CN108358827A (zh) * | 2018-05-07 | 2018-08-03 | 日照市普达医药科技有限公司 | 一种治疗牛皮癣的2-氧代-吲哚类衍生物及其制备方法 |
US20230009626A1 (en) * | 2018-10-05 | 2023-01-12 | Ichnos Sciences S.A. | Indolinone compounds for use as map4k1 inhibitors |
WO2021198253A1 (en) | 2020-04-01 | 2021-10-07 | Boehringer Ingelheim International Gmbh | Use of biomarkers in the treatment of fibrotic conditions |
CN111848490B (zh) * | 2020-08-24 | 2021-09-24 | 江西国药有限责任公司 | 一种高纯度乙磺酸尼达尼布的制备方法 |
CN112574094B (zh) * | 2020-12-14 | 2022-07-01 | 成都大学 | 吲哚酮衍生物及其制药用途 |
WO2022158956A1 (ko) | 2021-01-25 | 2022-07-28 | 주식회사 나이벡 | 섬유화 예방 및 치료용 펩타이드 |
EP4098246A1 (en) | 2021-05-31 | 2022-12-07 | Lotus Pharmaceutical Co., Ltd. | Formulation of nintedanib |
CN115703758B (zh) * | 2021-08-12 | 2024-03-26 | 中国医学科学院药物研究所 | 一类用作激酶抑制剂的化合物及其制备方法和用途 |
WO2024037982A1 (en) | 2022-08-16 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulations of nintedanib for intraocular use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015500A1 (en) * | 1997-09-05 | 1999-04-01 | Glaxo Group Limited | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL96047C (US07585860-20090908-C00162.png) * | 1956-06-08 | |||
AU684950B2 (en) * | 1994-05-06 | 1998-01-08 | Alcon Laboratories, Inc. | Use of vitamin E tocopheryl derivatives in ophthalmic compositions |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
WO1997025986A1 (fr) * | 1996-01-17 | 1997-07-24 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs d'epaississement de l'intima |
DE19815020A1 (de) * | 1998-04-03 | 1999-10-07 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19816624A1 (de) * | 1998-04-15 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
-
2000
- 2000-09-10 UA UA2002053890A patent/UA75054C2/uk unknown
- 2000-10-09 WO PCT/EP2000/009867 patent/WO2001027081A1/de active IP Right Grant
- 2000-10-09 HU HU0204587A patent/HU230416B1/hu active Protection Beyond IP Right Term
- 2000-10-09 PT PT00971347T patent/PT1224170E/pt unknown
- 2000-10-09 CA CA002387013A patent/CA2387013C/en not_active Expired - Lifetime
- 2000-10-09 KR KR1020077017807A patent/KR100857734B1/ko active IP Right Grant
- 2000-10-09 DK DK00971347.0T patent/DK1224170T5/en active
- 2000-10-09 ES ES00971347T patent/ES2331459T3/es not_active Expired - Lifetime
- 2000-10-09 AU AU10233/01A patent/AU781939B2/en active Active
- 2000-10-09 EA EA200200380A patent/EA006080B1/ru not_active IP Right Cessation
- 2000-10-09 RS YUP-266/02A patent/RS51013B/sr unknown
- 2000-10-09 SI SI200031039T patent/SI1224170T1/sl unknown
- 2000-10-09 BR BRPI0014735 patent/BRPI0014735B8/pt active IP Right Grant
- 2000-10-09 KR KR1020027004701A patent/KR100835546B1/ko active IP Right Grant
- 2000-10-09 MX MXPA02002799A patent/MXPA02002799A/es active IP Right Grant
- 2000-10-09 ME MEP-454/08A patent/MEP45408A/xx unknown
- 2000-10-09 JP JP2001530102A patent/JP4021664B2/ja not_active Expired - Lifetime
- 2000-10-09 NZ NZ518489A patent/NZ518489A/en not_active IP Right Cessation
- 2000-10-09 IL IL14875600A patent/IL148756A0/xx active IP Right Grant
- 2000-10-09 EP EP09164507A patent/EP2157081A1/de not_active Withdrawn
- 2000-10-09 EE EEP200200197A patent/EE05427B1/xx active Protection Beyond IP Right Term
- 2000-10-09 PL PL355433A patent/PL207445B1/pl not_active IP Right Cessation
- 2000-10-09 CZ CZ20021410A patent/CZ301073B6/cs unknown
- 2000-10-09 DE DE50015711T patent/DE50015711D1/de not_active Expired - Lifetime
- 2000-10-09 AT AT00971347T patent/ATE439342T1/de active
- 2000-10-09 CN CNB008158681A patent/CN100455568C/zh not_active Expired - Lifetime
- 2000-10-09 EP EP00971347.0A patent/EP1224170B9/de not_active Expired - Lifetime
- 2000-10-09 SK SK646-2002A patent/SK287312B6/sk not_active IP Right Cessation
- 2000-10-11 EG EG2000101293A patent/EG25931A/xx active
- 2000-10-11 PE PE2000001088A patent/PE20010671A1/es not_active IP Right Cessation
- 2000-10-11 MY MYPI20004762A patent/MY127956A/en unknown
- 2000-10-12 CO CO00077925A patent/CO5261488A1/es not_active Application Discontinuation
- 2000-10-12 TW TW089121320A patent/TWI268922B/zh active
- 2000-10-13 AR ARP000105394A patent/AR026036A1/es active Pending
-
2001
- 2001-02-06 SA SA01210704A patent/SA01210704B1/ar unknown
-
2002
- 2002-03-19 IL IL148756A patent/IL148756A/en active Protection Beyond IP Right Term
- 2002-04-05 BG BG106587A patent/BG65983B1/bg active Active
- 2002-04-10 HR HR20020306A patent/HRP20020306B1/xx not_active IP Right Cessation
- 2002-04-11 NO NO20021719A patent/NO322746B1/no active Protection Beyond IP Right Term
-
2003
- 2003-06-30 HK HK03104649.4A patent/HK1052505B/zh not_active IP Right Cessation
-
2007
- 2007-08-15 JP JP2007211755A patent/JP2007302697A/ja active Pending
-
2009
- 2009-11-06 CY CY20091101152T patent/CY1110067T1/el unknown
-
2015
- 2015-03-13 CY CY2015009C patent/CY2015009I2/el unknown
- 2015-03-16 NL NL300725C patent/NL300725I2/nl unknown
- 2015-03-16 LU LU92681C patent/LU92681I2/xx unknown
- 2015-03-16 FR FR15C0024C patent/FR15C0024I2/fr active Active
- 2015-03-16 BE BE2015C018C patent/BE2015C018I2/fr unknown
- 2015-03-18 NO NO2015009C patent/NO2015009I1/no unknown
-
2016
- 2016-05-13 HU HUS1600022C patent/HUS1600022I1/hu unknown
-
2023
- 2023-09-05 NO NO2023033C patent/NO2023033I1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015500A1 (en) * | 1997-09-05 | 1999-04-01 | Glaxo Group Limited | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100857734B1 (ko) | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법 | |
US6762180B1 (en) | Substituted indolines which inhibit receptor tyrosine kinases | |
JP3952369B2 (ja) | 新規な置換インドリノン類、その製造及びその薬剤としての使用 | |
US7148249B2 (en) | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments | |
AU764782B2 (en) | Substituted indolinones, the production thereof and their use as medicaments | |
JP2004525173A (ja) | 6位で置換されたインドリノン、それらのキナーゼインヒビターとしての使用 | |
MXPA04012937A (es) | Derivados de indolinona sustituidos en la posicion 6, su preparacion y su uso como medicamentos. | |
JP2005537276A (ja) | 6−置換インドリノン誘導体、その製法及び医薬組成物としての使用 | |
US7514468B2 (en) | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | |
DE10042696A1 (de) | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120827 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20130823 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140822 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20150821 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160829 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170825 Year of fee payment: 10 |